II
112th CONGRESS
1st Session
S. 373
IN THE SENATE OF THE UNITED STATES
February 16, 2011
Mr. Rockefeller (for himself, Mrs. Shaheen, Mr. Leahy, Mr. Inouye, Ms. Stabenow, and Mr. Schumer) introduced the following bill; which was read twice and referred to the Committee on Health, Education, Labor, and Pensions
A BILL
To amend the Federal Food, Drug, and Cosmetic Act to prohibit the marketing of authorized generic drugs.
Short title
This Act may be cited as the
Fair Prescription Drug Competition
Act
.
Prohibition of authorized generics
In general
Section 505 of the Federal Food, Drug, and Cosmetic Act (21 U.S.C. 355) is amended by adding at the end the following:
Prohibition of authorized generic drugs
In general
Notwithstanding any other provision of this Act, no holder of a new drug application approved under subsection (c) shall manufacture, market, sell, or distribute an authorized generic drug, directly or indirectly, or authorize any other person to manufacture, market, sell, or distribute an authorized generic drug.
Authorized generic drug
For purposes of this subsection, the term authorized generic drug—
means any version of a listed drug (as such term is used in subsection (j)) that the holder of the new drug application approved under subsection (c) for that listed drug seeks to commence marketing, selling, or distributing, directly or indirectly, after receipt of a notice sent pursuant to subsection (j)(2)(B) with respect to that listed drug; and
does not include any drug to be marketed, sold, or distributed—
by an entity eligible for 180-day exclusivity with respect to such drug under subsection (j)(5)(B)(iv); or
after expiration or forfeiture of any 180-day exclusivity with respect to such drug under such subsection (j)(5)(B)(iv).
.
Conforming amendment
Section 505(t)(3) of the Federal Food, Drug, and
Cosmetic Act (21 U.S.C. 355(t)(3)) is amended by striking In this
section
and inserting In this subsection
.